Translator Disclaimer
13 July 2009 Prevention of bladder tumor implantion after fluorescence-guided TUR with photodynamic therapy
Author Affiliations +
Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73801V (2009)
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States
The prevalence of bladder cancer is very high, due to its high recurrence rate in superficial bladder cancer (30 to 85%), which is the staging of approximately 80% of the patients at first diagnosis. Risk of recurrence and progression is associated with grade, stage, presence of concomitant carcinoma in situ, size and number of lesions, as well as time to first recurrence. Recurrences can be partly attributed to new occurrences but also to residual tumors after resection. Incomplete tumor removal has been observed in 30 to 50% of TUR's, especially when dealing with T1 or poorly visible malignant or pre-malignant disease1. Fluorescence guided resection with 5 amino levulinic acid (ALA) or its hexyl ester derivative (Hexvix, has now unequivocally been demonstrated to increase detection rate and a growing number of studies indicate this has a positive impact on recurrence and progression ratesImplantation of viable tumor cells, dispersed during resection, is a third factor influencing bladder cancer recurrence. The aim of early intravesical therapy is to interfere with cell viability and thus reduce implantation risks.
© (2009) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Saoussen Berrahmoune, Lina Bezdetnaya, Peter de Witte, Agnès Leroux, Dominique Dumas, François Guillemin, and Marie Ange D'Hallewin "Prevention of bladder tumor implantion after fluorescence-guided TUR with photodynamic therapy", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73801V (13 July 2009);

Back to Top